SCHEMBL6017223

SCHEMBL6017223

CN1[C@@H]2CCC[C@@]1(OC(=O)c1cc(Cl)cc(Cl)c1)CC2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 4/20 0.46
HTR3E A5X5Y0 2/20 0.46
HTR3B O95264 2/20 0.46
CYP1A2 P05177 2/20 0.46
HTR3A P46098 2/20 0.46
HTR3D Q70Z44 2/20 0.46
HTR3C Q8WXA8 2/20 0.46
GMNN O75496 1/20 0.46
ALOX15 P16050 1/20 0.46
TSHR P16473 1/20 0.46
MTOR P42345 1/20 0.46
PMP22 Q01453 1/20 0.46
HSD17B10 Q99714 1/20 0.46
GAA P10253 1/20 0.45
POLB P06746 1/20 0.43
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36
L3MBTL1 Q9Y468 2/20 0.33
CYP2C19 P33261 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL467252 0.86 CYP1A2 (0.45) CYP2D6HTR3EHTR3BCYP1A2HTR3A
SCHEMBL9640284 0.82 CHRM2 (0.46) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL1851579 0.80 KMT2A (0.39) POLBSLC6A4SLC6A3L3MBTL1MEN1
SCHEMBL5787516 0.76 ATM (0.41) CYP1A2TSHRSLC6A2SLC6A4SLC6A3
SCHEMBL4785273 0.73 NPC1 (0.41) CYP1A2TSHRCYP2C19MEN1KMT2A
Hydrochloric Acid SCHEMBL9378806 0.73 KMT2A (0.39) CYP2D6TSHRHSD17B10GAAPOLB
SCHEMBL10972643 0.72 TAS1R3 (0.38) CYP2D6HTR3EHTR3BCYP1A2HTR3A
Hydrochloric Acid SCHEMBL9375902 0.71 SMYD3 (0.36) TSHRMEN1KMT2A
Hydrochloric Acid SCHEMBL9373976 0.71 CNR2 (0.37) LMNACHRNA4
SCHEMBL4233804 0.70 TAS1R3 (0.38) TSHRHSD17B10L3MBTL1NR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1660079-A2 COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A SEROTONIN MODULATING AGENT FOR THE TREATMENT OF NEOPLASIA Pharmacia Corporation (US) 2006-05-31 EP claimed
US-20050085477-A1 Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of neoplasia PHARMACIA CORPORATION 2005-04-21 US claimed
WO-2005018569-A2 COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A SEROTONIN MODULATING AGENT FOR THE TREATMENT OF NEOPLASIA PHARMACIA CORPORATION (US) 2005-03-03 WO claimed
EP-1660079-A2 COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A SEROTONIN MODULATING AGENT FOR THE TREATMENT OF NEOPLASIA Pharmacia Corporation (US) 2006-05-31 EP disclosed
US-20050085477-A1 Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of neoplasia PHARMACIA CORPORATION 2005-04-21 US disclosed
WO-2005018569-A2 COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A SEROTONIN MODULATING AGENT FOR THE TREATMENT OF NEOPLASIA PHARMACIA CORPORATION (US) 2005-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050085477-A1 Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of neoplasia TPH2, TPH1, HTR2A CYP2D6 873/4885HTR3E 18/4885HTR3B 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.